Suvorexant: a promising, novel treatment for insomnia.

Document Type

Article

Abstract

Suvorexant a novel, orexin receptor antagonist was recently approved by the US Food and Drug Administration for the treatment of sleep onset and sleep maintenance insomnia in August 2014. Multiple animal and human studies support the efficacy, safety, and tolerability of suvorexant for patients of various profiles. Current recommendations advocate for a starting dose of 10 mg and a maximum dose of 20 mg, with cautious use in women, obese patients, and patients taking other CYP3A4 inhibitors. More head-to-head studies comparing suvorexant to other sedative-hypnotic therapies are needed to further delineate which patients will benefit the most from this medication over others.

Publication Date

1-1-2016

Publication Title

Neuropsychiatr Dis Treat

ISSN

1176-6328

Volume

12

First Page

491

Last Page

495

PubMed ID

26955275

Digital Object Identifier (DOI)

10.2147/NDT.S31495

This document is currently not available here.

Share

COinS